| Date | Price Target | Rating | Analyst |
|---|
Guggenheim resumed coverage of Five Prime Therapeutics with a rating of Neutral and set a new price target of $38.00
Jefferies Financial Group resumed coverage of Five Prime Therapeutics with a rating of Hold and set a new price target of $38.00
Guggenheim downgraded Five Prime Therapeutics from Buy to Neutral and set a new price target of $38.00
Guggenheim downgraded Five Prime Therapeutics from Buy to Neutral
Jefferies downgraded Five Prime Therapeutics from Buy to Hold and set a new price target of $38.00
Jefferies Financial Group downgraded Five Prime Therapeutics from Buy to Hold
Wedbush downgraded Five Prime Therapeutics from Outperform to Neutral
Wells Fargo & Company downgraded Five Prime Therapeutics from Overweight to Equal Weight
4 - FIVE PRIME THERAPEUTICS, INC. (0001175505) (Issuer)
4 - FIVE PRIME THERAPEUTICS, INC. (0001175505) (Issuer)
4 - FIVE PRIME THERAPEUTICS, INC. (0001175505) (Issuer)
4 - FIVE PRIME THERAPEUTICS, INC. (0001175505) (Issuer)
4 - FIVE PRIME THERAPEUTICS, INC. (0001175505) (Issuer)
4 - FIVE PRIME THERAPEUTICS, INC. (0001175505) (Issuer)
4 - FIVE PRIME THERAPEUTICS, INC. (0001175505) (Issuer)
4 - FIVE PRIME THERAPEUTICS, INC. (0001175505) (Issuer)
4 - FIVE PRIME THERAPEUTICS, INC. (0001175505) (Issuer)
4 - FIVE PRIME THERAPEUTICS, INC. (0001175505) (Issuer)